Related Experiment Video
Updated: Nov 5, 2025
Systematic Hearing Performance Evaluation Process for Adolescents with Cochlear Implantation at Early Ages
Published on: March 24, 2023
Achieving optimal vaccine administration in a pediatric cochlear implant program after implementation of a Quality
Rachel St John1, Ron B Mitchell2, Kenneth Lee3
1University of Texas Southwestern Medical Center/Children's Health Medical Center Dallas, 2350 Stemmons Fwy, F6208, Dallas, TX, 75207, USA.
Insights
A quality improvement project successfully increased vaccination compliance for the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in children with cochlear implants. This initiative, followed by ongoing oversight, eliminated missed vaccinations, reducing meningitis risks.
Area of Science:
- Pediatric Otolaryngology
- Vaccinology
- Quality Improvement Science
Background:
- Children with cochlear implants are at increased risk for meningitis.
- Vaccination compliance is crucial for preventing meningitis-related complications in this vulnerable population.
- Existing vaccination protocols may have gaps in ensuring timely administration of vaccines like the 23-valent pneumococcal polysaccharide vaccine (PPSV-23).
Purpose of the Study:
- To enhance vaccination compliance for the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in pediatric cochlear implant recipients.
- To implement and evaluate a Quality Improvement (QI) project aimed at improving PPSV-23 administration.
- To minimize meningitis-related complications through maximized vaccination coverage.
Main Methods:
- A QI project was conducted from December 2018 to January 2020, involving children aged 0-21 years undergoing cochlear implantation.
- Electronic medical record (EMR) prompts and protocols were developed for physicians and nurses to review and document vaccine status.
- Regular chart reviews, feedback cycles, and the development of an EMR registry were employed for surveillance and compliance monitoring.
Main Results:
- Initial vaccine documentation compliance improved significantly, from 61% to 90% for physicians and 20% to 91% for nurses, after the first cycle.
- Compliance showed fluctuations but ultimately peaked at 83% for physicians and 100% for nurses by the final cycle.
- During the QI project, only one child missed the PPSV-23 vaccine, who was subsequently identified and vaccinated. Post-project, a formal oversight program achieved 100% compliance over 13 months.
Conclusions:
- A structured QI project, followed by a dedicated vaccination oversight program, effectively eliminated missed PPSV-23 vaccinations in children with cochlear implants.
- This systematic approach ensures high vaccination rates, thereby mitigating the risk of meningitis-related complications.
- Cochlear implant programs are encouraged to adopt similar strategies to improve patient safety and outcomes.
Objectives:
To maximize vaccination compliance in children undergoing cochlear implantation and thus minimize meningitis-related complications. To present a Quality Improvement (QI) Project for 23-valent pneumococcal polysaccharide vaccine (PPSV-23) administration within a pediatric cochlear implant program.
Methods:
We identified children from birth through 21 years of age with cochlear implants or cochlear implant candidates who were seen at Children's Health Medical Center/UT Southwestern Medical Center, Dallas between 12/2018 and 01/2020. Protocols were developed for physicians and nurses using electronic medical record (EMR) smart phrases with prompts to review and document vaccine status and plan. Charts were reviewed for six consecutive cycles of 6-12 weeks for vaccine documentation and plan compliance. Regular feedback was provided to physicians and nurses. A cochlear implant EMR registry was developed for increased surveillance of vaccine administration.
Results:
Physicians and nurses showed an improvement in vaccine documentation from the start of the project to the first data cycle review (61%-90% and 20%-91% for physicians and nurses respectively). This was followed by a regression in the third to fourth review cycles (decrease to 67% and 80% compliance). Vaccine documentation compliance improved after subsequent review and feedback, and peaked during the final cycle of the review (83% and 100% compliance). During the year-long QI project, one child with a cochlear implant missed the PPSV-23 vaccine but was identified during cycle review and vaccinated. This occurred during the third cycle, and for the remaining three cycles there were no missed vaccinations. On completion of the QI project, a formal vaccination oversight program was introduced with a physician/nurse team that reviews the cochlear implant EMR registry monthly for children who have not been vaccinated. In the 13 months since the completion of the QI project there has been 100% compliance with no children who missed vaccination.
Conclusion:
We present a vaccination program with oversight to address missed vaccinations. Implementation of a QI project followed by transition to a formal vaccination oversight program eliminated missed PPSV-23 vaccinations in children with cochlear implants. We recommend that cochlear implant programs use similar approaches to ultimately minimize potential meningitis-related complications in patients with cochlear implants.
